Medicine
Volume 37, Issue 4 , Pages 186-189, April 2009

Myelodysplastic disorders

Sally B Killick MD FRCP FRCPath is Consultant Haematologist at the Royal Bournemouth Hospital NHS Foundation Trust, Bournemouth, UK. Competing interests: Dr Killick has sat on advisory boards for Celgene Novartis

Abstract 

The myelodysplastic syndromes (MDS) are clonal disorders of haemopoiesis. They share characteristic morphological abnormalities of the blood and bone marrow and a risk of evolution to acute leukaemia, which varies depending on the sub-type of MDS. The majority of patients are elderly and present with symptoms of marrow failure despite increased marrow cellularity. The World Health Organization has published a classification of MDS, which incorporates morphological, genetic and clinical features. This has been adopted worldwide. In combination with the International Prognostic Scoring System, the prognosis of the disease can be estimated and appropriate treatment offered. This treatment should be tailored to the individual patient.

Keywords: 5q– syndrome, chronic myelomonocytic leukaemia, epigenetic therapy, International Prognostic Scoring System, lenalidomide, myelodysplastic syndrome

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1357-3039(08)00360-5

doi:10.1016/j.mpmed.2008.12.003

Medicine
Volume 37, Issue 4 , Pages 186-189, April 2009

Article Tools

* Image Usage & Resolution